AI-powered search
Try Polaris, our new AI-powered search!

Would you consider using ruxolitinib instead of TCS with a patient on dupilumab for breakthrough flares?

Featuring Peter Lio, MD |

Clinical Assistant Professor of Dermatology Pediatrics 
Northwestern University Feinberg School of Medicine
Chicago, IL

| Published December 22, 2022

Loading...

Related CME